Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000518

Drug Information
NameFlecainide
SynonymsFlecainida; LS-27388; SMP1_000074; Flecainide [INN:BAN]; CCRIS 313; Flecainide (INN); CHEBI:127588; AC-16019; BCBcMAP01_000189; AC1L1FQZ; KBioGR_000037; D07962; NCGC00025175-06; UNII-K94FTS1806; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; 54143-55-4; Flecainida [INN-Spanish]; KBio2_005173; KBio2_000037; Prestwick3_000735; DB01195; Tambocor; HMS1791B19; Lopac0_000546; BSPBio_001317; 99495-87-1; 54143-56-5 (monoacetate); KBio2_002605; HMS2089E17; Bio1_000864; (+-)-Flecainide; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; Flecaine; IDI1_033787; R818; SPBio_002629; CID3356; BRD-A09472452-015-03-6; C17H20F6N2O3; KBioSS_000037; flecainide; Flecainidum; HMS1989B19; NCGC00025175-03; C07001; AB00513907; BPBio1_000760; Prestwick0_000735; CHEMBL652; Bio2_000037; KBio3_000073; MolPort-003-847-380; KBio3_000074; Prestwick1_000735; NSC719273; BSPBio_000690; Prestwick2_000735; Bio2_000517; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; BRD-A09472452-001-02-8; Bio1_000375; Bio1_001353; NCGC00025175-05; Flecainidum [INN-Latin]; N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; NCGC00025175-04; TL80090300
Trade NameTambocor; Almarytm; Apocard; Ecrinal; Flíž|caine
Company3M pharmaceuticals
IndicationTachyarrhythmias
[ICD9: 427, 785.0   ICD10: I47-I49, R00.0]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(
7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25
,26)
InChIKeyDJBNUMBKLMJRSA-UHFFFAOYSA-N
Canonical SMILESC1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F    
Therapeutic ClassAnti-Arrhythmia Agents
CAS NumberCAS 54143-55-4
FormulaC17H20F6N2O3
PubChem Compound IDCID 3356.
PubChem Substance IDSID 9214.
SuperDrug ATC IDC01BC04
SuperDrug CAS ID054143554;
TargetSodium channel protein type 5 subunit alphaBlocker[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075442 To Reference
Ref 2Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543